Micromet (MITI) Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients
Tweet Send to a Friend
Micromet, Inc. (Nasdaq: MITI) last week presented an update from an ongoing clinical study of the BiTE(R) antibody blinatumomab (MT103) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
